Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response

Hamed, Elham O.; Ahmed, Hydi; Sedeek, Osama B; Mohammed, Abeer M; Abd-Alla, Ali A; Ghaffar, Hazem M Abdel

doi:10.1186/1746-1596-8-11

Cited by 76 publications

(62 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the present study, the CA 125 showed the same sensitivity of HE4 (92%), this result is consistent with the study by Karlsen et al (2012) However, this shows consistency with previous studies, as the study by Fujiwara et al (2015), who found that the AUCs for HE4 were better than the AUC for CA 125 in distinguishing between benign diseases and EOC, the study by Hamed et al (2013) AUC values were (0.96) for HE4 and (0.82) for (CA 125), the study by Karlsen et al (2012) AUC was highest for RMI (0.905) followed by HE4 (0.864) and CA125 (0.854), respectively and for the Montagnana et al (2009) study, AUC for HE4 is higher than CA 125. There was a highly significance (r = 0.746, p<0.001) correlation between levels of CA 125 and tissue HE4 measured by real time PCR in all groups of the study.…”

Section: Int J Cancersupporting

confidence: 83%

“…There was a highly significance (r = 0.746, p<0.001) correlation between levels of CA 125 and tissue HE4 measured by real time PCR in all groups of the study. In study by Hamed et al (2013) a positive correlation between serum levels of HE4 and CA 125 was observed in women with epithelial ovarian cancer, benign gynaecological disease group and control group (r = 0.5, p<0.01) which was consistent with the present study results.…”

Section: Int J Cancersupporting

confidence: 82%

See 1 more Smart Citation

Human Epididymis Protein 4 (HE4) mRNA as a Prognostic Marker in Ovarian Tumors in Relation to RMI and CA125

Yehia¹,

Mansour²,

Mekawy³

2015

International J. of Cancer Research

View full text Add to dashboard Cite

Human Epididymis protein 4 (HE4) has recently been shown to improve the sensitivity and specificity of Epithelial Ovarian Cancer (EOC) diagnosis but its function in cancer cells is not clear. We evaluated HE4 expression, RMI and CA125 serum level as diagnostic tools of primary ovarian cancer in Egyptian women. The HE4 gene expression was evaluated by real time PCR in ovarian cancer of 50 Egyptian women. Ovarian cancer tissues were studied for the detection of the gene expression of HE4 by Quantitative Real Time PCR (Q RT-PCR). Serum Human cancer antigen 125 (CA 125) was measured in the serum of all participants of the study using immune sorbent assay (ELISA). The HE4 showed significant difference among ovarian malignant tumors patients compared to the control subjects (p<0.01). The best cutoff value 0.053 at which HE4 sensitivity was 92% and specificity was 96%. There was a significance correlation between HE4, RMI and CA125 in all patients of the study (p#0.01 for both). The mRNA expression of HE4 was significantly high versus the control group in early stages and low grades of the disease (p = 0.00, 0.01, respectively). As well as, there was Increased HE4 expression in the late stages of the disease suggesting that it may be associated with poor prognosis as well. The HE4 could be considered as a good prognostic marker for ovarian cancer that increases the sensitivity of the CA 125 to absolute value without affection of CA125 accuracy and its positive predictive value.

show abstract

Section: Int J Cancersupporting

confidence: 83%

Section: Int J Cancersupporting

confidence: 82%

Human Epididymis Protein 4 (HE4) mRNA as a Prognostic Marker in Ovarian Tumors in Relation to RMI and CA125

Yehia¹,

Mansour²,

Mekawy³

2015

International J. of Cancer Research

View full text Add to dashboard Cite

show abstract

“…However, serum HE4 levels rarely increased in benign gynecologic conditions, suggesting its complementary role to CA125 [13][14][15] . Similar to CA125, HE4 levels were significantly higher in patients with ovarian cancer compared with levels observed in patients with benign disease or healthy controls 16 .…”

Section: Resultsmentioning

confidence: 65%

Serum HE4 is more suitable as a biomarker than CA125 in Chinese women with benign gynecologic disorders

Zhang¹,

Qiao²,

Li³

et al. 2015

Afr H. Sci.

View full text Add to dashboard Cite

Objective: This study measured the human epididymis protein 4 (HE4) and CA125 levels in Chinese women with benign gynecological disorders. Material and methods: Sera were obtained from Chinese women prior to surgery for a pelvic mass and HE4 and CA125 levels were determined. The proportions of patients with HE4 and CA125 levels were compared. Results: There were 68 Chinese women with benign diseases. HE4 levels were less elevated than CA125 (1% V.S. 29%, P<0.001). The significant difference was observed in patients with endometriosis/endometriomas in which HE4 was not elevated patients and CA125 was elevated in 53% (P<0.001). Serum HE4 level was not elevated in patients with cystadenoma (0% V.S. 23%, P<0.001) and in patients with germ cell tumors (0% V.S. 5%, P<0.001). Conclusion: HE4 was less elevated and more suitable as a biomarker than CA125 in chinese women with benign disease.

show abstract

“…Confirmation of this HE4 behaviour in a larger number of patients is therefore required. The suggestion that HE4 is a good indicator for the remission from the disease was reported by a follow up study by Hamed et al 18 in which it was shown that the values of HE4 correlated with the clinical response to treatment or remission from the disease, as documented by CT imaging.…”

Section: 11mentioning

confidence: 85%

Clinico-pathological correlation of ovarian tumors and tumor like lesions with role of CA125 and HE4 as biomarkers for discrimination of benign and malignant ovarian tumors

et al. 2018

View full text Add to dashboard Cite

Background: Ovarian tumors and tumor like lesions of ovary frequently form pelvic masses and are associated with hormonal manifestations. Clinically or surgically they can mimic malignancy but pathologically they could be benign tumors or tumor like lesions.Methods: The aim of present study is to do clinico-histopathological correlation of ovarian tumors and tumor like lesions of ovary and also evaluate the role of serum CA125, HE4 and calculate risk of ovarian malignancy algorithm (ROMA), for differentiation of benign and malignant ovarian tumors.233 cases of ovarian tumors and tumor like lesions were studied. Tumors were classified according to WHO classification. Clinical and histological findings were compiled on proforma and subjected to analysis.Results: In present study, out of total 233 cases, 41.2% were ovarian tumors and 58.8% tumor like lesions of ovary. Among tumor like lesions, follicular cyst was commonest lesion while among ovarian tumors, benign serous surface epithelial tumor was commonest. In patients with ovarian tumors, blood samples were collected, before and after the treatment for analysis of CA125, HE4 and ROMA.Conclusions: Serum values of CA125and HE4 as well as ROMA were highly elevated in women with malignant epithelial tumors as compared to women with benign lesions. Also, all the parameters i.e. HE4, CA125 and ROMA showed significant difference before and after surgery. Hence measuring serum HE4 and CA125 along with ROMA calculation may provide higher accuracy for detecting malignant epithelial ovarian tumor.

show abstract

Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response

Cited by 76 publications

References 41 publications

Human Epididymis Protein 4 (HE4) mRNA as a Prognostic Marker in Ovarian Tumors in Relation to RMI and CA125

Human Epididymis Protein 4 (HE4) mRNA as a Prognostic Marker in Ovarian Tumors in Relation to RMI and CA125

Serum HE4 is more suitable as a biomarker than CA125 in Chinese women with benign gynecologic disorders

Clinico-pathological correlation of ovarian tumors and tumor like lesions with role of CA125 and HE4 as biomarkers for discrimination of benign and malignant ovarian tumors

Contact Info

Product

Resources

About